Poster presentation at the ALS Association’s ALS Nexus conference, August 23-26 Disclosed that NRG5051 acts by inhibiting the mPTP through a novel NLRX1-mediated mechanism of action Data showed that NRG5051 displays profound anti-inflammatory and neuroprotective effects in ALS mouse models Stevenage, UK, 24 August 2026 – NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience […]

Stevenage, UK, 8 January 2026 – NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a […]

Stevenage, UK, 23 October 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; […]

First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative diseases NRG5051 prevents mitochondrial dysfunction via inhibition of the mitochondrial permeability transition pore (mPTP) through a novel protein target Inhibition of the mPTP in the brain prevents neuronal cell death […]

Stevenage, UK, 26 April 2023 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has appointed Jonathan Savidge Ph.D to its Board of Directors as independent Non-Executive Chair. Jonathan’s appointment reflects the maturation of the company, having closed its series A financing of £16m in late 2022. […]